In the previously review period we completed a Phase I and II clinical trial targeting telomerase in non-small cell lung cancer (NSCLC). The results of these trials validated modulating telomere biology as an important target in lung cancer. NSCLC patients with short telomeres have poorer progression free and overall survival compared to patients with longer telomeres. In our completed Phase II trial we determined that the patients with the shortest telomeres trended to having better overall responses to our telomerase inhibitor. These results have encouraged us to pursue other novel mechanisms to modulate telomere biology and this is the focus of this renewal project. We also have been conducting preclinical studies on cancer stem cell biomarkers in NSCLC. We have identified ALDH1A1 and ALDH1A3 as candidate lung cancer stem cell biomarkers whose expression correlates with a poor prognosis in lung cancer patients with resected Stage I disease. These putative cancer stem cell populations are telomerase positive with activated Wnt and Hh activated pathways and we have experimental support for the hypothesize that our telomerase inhibitors not only target the bulk of the lung cancer cells but also the stem cell pool. We also have specific inhibitors against ALDH and will test these for reducing clonogenicity and tumorigenicity in direct (never in cell culture) xenografts and in ROCK inhibitor established primary lung cancers. We have a strong commitment and proven track record of being able to advance telomerase inhibitors to clinical trials. We will now progress our patented telomerase inhibitors (telomere modulators) and stem cell candidate therapies. This will include a WNT inhibitor, IWR-1 that targets tankyrase (PARP5A), a telomere associated protein. We will also advance 6-thio-2'deoxyguanosine (6-thio-dG) that is a nucleoside-based telomerase substrate. Both 6-thio-dG and IWR-1 treatments show increased specificity to telomerase expressing cancer cells over normal telomerase silent cells. Both lead to telomere shortening and reduced in vitro and in vivo cell growth. Our long-term goal is to maximize telomere shortening or uncapping and to determine the most effective way to use these SPORE developed inhibitors clinically in patients with NSCLC.

Public Health Relevance

The ability of cancer cells to divide indefinitely is one of the key hallmarks of cancer. Telomerase is the enzyme that permits indefinite divisions in all stages of lung adenocarcinoma. We propose to advance our preclinical studies with two patented home institution developed novel inhibitors as well as cancer stem cell inhibitors and to advance these to clinical trials in lung cancer patients during the next review period.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Sw Medical Center Dallas
United States
Zip Code
Skoulidis, Ferdinandos; Goldberg, Michael E; Greenawalt, Danielle M et al. (2018) STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8:822-835
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999
Ferdosi, Shadi; Rehder, Douglas S; Maranian, Paul et al. (2018) Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, ?1-4 Branching, ?1-6 Branching, and ?2-6 Sialylation in Cancer. J Proteome Res 17:543-558
Zhou, Xiaorong; Padanad, Mahesh S; Evers, Bret M et al. (2018) Modulation of Mutant KrasG12D -Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function. Mol Cancer Res :
Abrams, Zachary B; Zucker, Mark; Wang, Min et al. (2018) Thirty biologically interpretable clusters of transcription factors distinguish cancer type. BMC Genomics 19:738
Pietanza, M Catherine; Waqar, Saiama N; Krug, Lee M et al. (2018) Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol 36:2386-2394
Huang, Fang; Ni, Min; Chalishazar, Milind D et al. (2018) Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. Cell Metab 28:369-382.e5
Tanaka, Ichidai; Sato, Mitsuo; Kato, Toshio et al. (2018) eIF2?, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Sci 109:1843-1852
Pozo, Karine; Minna, John D; Johnson, Jane E (2018) Identifying a missing lineage driver in a subset of lung neuroendocrine tumors. Genes Dev 32:865-867
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646

Showing the most recent 10 out of 1059 publications